HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Puig-Basagoiti, F. Articles by Saiz, J.-C. Search for Related Content PubMed PubMed Citation Articles by Puig-Basagoiti, F. Articles by Saiz, J.-C. Agricola Articles by Puig-Basagoiti, F. Articles by Saiz, J.-C.

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C

Ivana Furi

Juan-Carlos Saiz

Liver Unit, Institut de Malalties Digestives, Departament de Medicina (IMD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain

Correspondence
Juan-Carlos Saiz
jcsaiz{at}inia.es

The quasispecies nature of hepatitis C virus (HCV) may have important implications concerning resistance to antiviral agents. To determine whether HCV NS5A quasispecies composition and dynamics are related to responsiveness to combined interferon (IFN) and ribavirin therapy, extensive sequence analyses of cloned RT-PCR amplification products of HCV-1b NS5A quasispecies of sequential isolates from 15 treated (nine sustained responders and six non-responders) and three untreated patients were performed. Accumulation of mutations in NS5A during therapy was relatively frequent in the V3 domain, but unusual elsewhere. Amino acid changes were the result of the imposition of minor variants that were already present before treatment and always occurred within the first week of therapy. Before treatment, the complexity and diversity of quasispecies were lower in isolates from responders than in those from non-responders, particularly in the V3 domain, where differences in nucleotide entropy (0·35 vs 0·64, P=0·003), genetic distance (0·0145 vs 0·0302, P=0·05) and non-synonymous substitutions (0·0102 vs 0·0203, P=0·036) were statistically significant. These differences became more apparent during treatment, because complexity and diversity remained stable or tended to increase in non-responders, whereas they tended to decrease in responders. These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy.

The GenBank/EMBL/DDBJ accession numbers for the HCV sequences reported in this study are AY378328–AY378694, AY378705–AY379066, AY381300–AY381643 and AY381644–AY381994.

Present address: Departamento de Biotecnología, Instituto Nacional de Investigaciones Agrarias (INIA), Ctra Coruña km 7·5, 28040 Madrid, Spain.

This article has been cited by other articles:

				P. Munoz de Rueda, J. Casado, R. Paton, D. Quintero, A. Palacios, A. Gila, R. Quiles, J. Leon, A. Ruiz-Extremera, and J. Salmeron Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment Responses J. Virol., July 1, 2008; 82(13): 6644 - 6653. [Abstract] [Full Text] [PDF]